991 resultados para Trials (Impeachment)


Relevância:

20.00% 20.00%

Publicador:

Resumo:

Mode of access: Internet.

Relevância:

20.00% 20.00%

Publicador:

Resumo:

[Leschinnky, a U-M freshman, set the record of :21.4 in the preliminary heat. There was a slight wind and his time was not officially recognized as a world record. He finished second in the finals and advance to the U.S. national trials at Boston.]

Relevância:

20.00% 20.00%

Publicador:

Resumo:

Mode of access: Internet.

Relevância:

20.00% 20.00%

Publicador:

Resumo:

On verso of each t.p.: London, Shackell and Arrowsmith; at end of v.1: Printed by W. Lewis; at end of v.2: Shackell and Arrowsmith; at end of v.3: J. and C. Adlard, printers; at end of v.4, and at foot of p.576; v.6: D. Sidney & Co., printers; at end of v.5: Whiting and Branston.

Relevância:

20.00% 20.00%

Publicador:

Resumo:

On seal: Navy Department, United States of America.

Relevância:

20.00% 20.00%

Publicador:

Resumo:

Objectives: To investigate the effectiveness of valerian for the management of chronic insomnia in general practice. Design: Valerian versus placebo in a series of n-of-1 trials, in Queensland, Australia. Results: Of 42 enrolled patients, 24 (57%) had sufficient data for inclusion into the n-of-1 analysis. Response to valerian was fair for 23 (96%) participants evaluating their 'energy level in the previous day' but poor or modest for all 24 (100%) participants' response to 'total sleep time' and for 23 (96%) participants' response to 'number of night awakenings' and 'morning refreshment'. As a group, the proportion of treatment successes ranged from 0.35 (95% CI 0.23, 0.47) to 0.55 (95% CI 0.43, 0.67) for the six elicited outcome sleep variables. There was no significant difference in the number (P = 0.06), distribution (P = 1.00) or severity (P = 0.46) of side effects between valerian and placebo treatments. Conclusions: Valerian was not shown to be appreciably better than placebo in promoting sleep or sleep-related factors for any individual patient or for all patients as a group. (C) 2003 Elsevier Ltd. All rights reserved.

Relevância:

20.00% 20.00%

Publicador: